The PCSK9 is one of the most important marks for the evolution of therapeutic agents for atherosclerosis because its interaction with low-density lipoprotein receptors causes atherosclerosis. Protein-ligand interactions help us to understand the true mechanism of pharmacological action. This study seeks to identify the most powerful suppression options for PCSK9. Initially, the reported ACE inhibitors were included in pharmacophore modeling using PharmaGist. Next, ZINCPHARMER was used to screen the selected model against a ZINC database to identify putative drug candidates docked to the target protein to understand the interactions. The 10 best pharmacological candidates for PCSK9 with a binding energy of 9.8-8.2 kcal mol-1 were identified by molecular docking and their pharmacokinetic properties and oral bioavailability were evaluated. The (S) severalplant obtained chemicals have been discovered, including anti-hypersensitive drugs such as “Canadine, Hesperetin, and Labetalol”. According to Biochemistry, these compounds formed a stable “protein-ligand” complex. The (S) canadine PCSK9 complex had the lowest RMSD and was the most stable. Future in vitro studies could identify (S) canadin as a promising atherosclerosis inhibitor for the evolution of novel PCSK9 inhibitors.
A muscle wasdissected from the Catla catlafish and enzyme hydrolysis was done using various digestive enzymes such as pepsisn, protease, papine, trypsin and alcalase at verity of time intervals (0th, 3rd, 6th, 9th and 12th) hour respectively. Followed by, the amino acid composition was identified and the confirmative assays such as, the anti-oxidant assays (DPPH and Hydroxy radical scavenging activity) and anti-inflammatory assays (HRBC and AD) were done for various peptide hydrolysate. The active hr was identified as 9th hr alcalase hydrolysate which was purified through Ultrafiltration (>30 kDa, 30-10 kDa, 10-3 kDa and <3 kDa). These fractions were again studied for its anti-oxidant and anti-inflammatory activity. Based on the results obtained, the active fraction was identified as 10-3kDa which was further purified and identified using Gel filtration chromatography and LC-MS/MS as HPAEDR (723.76 Da). Further, for in vitro and in vivo studies the peptide derived from CCM was synthetically designed with 98% purity (PhtdPeptides Co., Ltd. Zhemgzhou, China). Additionally, the physiochemical properties (Solubility, emulsifying properties and foaming properties) of these fraction was studied. Finally, the purified fraction was tested for in vitro activity through cell viability, COX-2 production, NO production and TNF-α production. Moreover, the in vivo protective effect is tested on Zebrafish larvae. The results suggest that the active purified peptide fraction isolated from Catla catla muscle has a strong natural anti-oxidant, anti-inflammatory and cholesterol reduction activity which can be used in functional foods and pharmaceuticals.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.